Vor Biopharma Inc.
NASDAQ:VORBiotechnology
-$0.34 today
- Market cap
- $966.13M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$2,053.13
Volume 0.79M
Average 1.07M
VOR Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Vor Biopharma Inc.NASDAQ: VOR
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $35.13M rose 5.5% year over year, behind the +210.2% change in trailing-twelve-month operating expenses. Sequentially, it fell 2.3% from the prior quarter. Over 3 fiscal years it compounded at +63.9% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +5.5% toward the trailing-twelve-month pace of +210.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 371.64M USD
- Year-over-year change
- +206.7%
- 4-year CAGR
- +52.3%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 371.64M | +206.7% |
| FY2024 | 2024-12-31 | 121.19M | -1.1% |
| FY2023 | 2023-12-31 | 122.54M | +45.1% |
| FY2022 | 2022-12-31 | 84.46M | +22.4% |
| FY2021 | 2021-12-31 | 69.02M | — |
Operating Expenses vs competitors
How VOR compares with its peers on the latest reported figures
- VOR's LTM Mar 2026 operating expenses of $373.48M is the 2nd highest of the 10 companies compared; the peer median is $213.72M.
- Its year-over-year change of +210.2% is the highest of 10, against a peer median of -11.7%.
- Over three fiscal years its annual growth of +63.9% compares with a peer median of -7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $389.17M | +13.2% | -15.6% | 1546.0% | |
| LTM Mar 2026 | $373.48M | +210.2% | +63.9% | — | |
| LTM Mar 2026 | $319.11M | -10.9% | -0.7% | 482.8% | |
| LTM Mar 2026 | $254.35M | -11.1% | +20.4% | 274.7% | |
| LTM Mar 2026 | $235.17M | +10.6% | -13.2% | — | |
| LTM Mar 2026 | $213.72M | -20.2% | -1.0% | — | |
| LTM Mar 2026 | $117.37M | -46.1% | -16.4% | 303.3% | |
| LTM Mar 2026 | $113.97M | -13.7% | -2.0% | — | |
| LTM Mar 2026 | $113.16M | -11.7% | -28.7% | 1791.7% | |
| LTM Mar 2026 | $87.08M | -41.0% | -7.2% | — | |
| Peer median (excluding VOR) | $213.72M | -11.7% | -7.2% | 482.8% | |
Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 8.96M | 3.49M | 0 | 0 |
| Gross Profit | 0 | (8.96M) | (3.49M) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 47.53M | 64.55M | 94.32M | 93.31M | 321.53M |
| Selling, General & Admin | 21.49M | 19.91M | 31.72M | 27.88M | 50.11M |
| Operating Expenses | 69.02M | 84.46M | 122.54M | 121.19M | 371.64M |
| Depreciation & Amortization | 1.43M | 8.96M | 3.49M | 3.53M | 2.89M |
| EBITDA | (67.47M) | (83.13M) | (114.37M) | (113.39M) | (693.09M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (69.02M) | (93.42M) | (126.04M) | (121.19M) | (371.64M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 119K | 1.32M | 8.17M | 4.27M | 5.87M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 119K | 1.32M | 8.17M | 4.27M | (324.34M) |
| Income Before Tax | (68.9M) | (92.09M) | (117.86M) | (116.91M) | (695.98M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (68.9M) | (92.09M) | (117.86M) | (116.91M) | (695.98M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (37.80) | (46.60) | (35.00) | (34.00) | (70.50) |
| EPS (Diluted) | (37.80) | (46.60) | (35.00) | (34.00) | (70.50) |
| Weighted Avg Shares | 1.86M | 1.98M | 3.36M | 3.44M | 9.87M |
| Weighted Avg Shares (Diluted) | 1.86M | 1.98M | 3.36M | 3.44M | 9.87M |
Vor Biopharma Inc.
NASDAQ:VOR
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.